AFP and liver cancer: Additional TCRL-based CAR-T examples targeting hematological malignancies and solid tumors can be found against the intracellular onco-protein WT1, specific liver cancer marker alpha-fetoprotein (AFP), and gp100, all showing promising results in pre-clinical studies (73–75).